14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SYRE vs VTYX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Spyre Therapeutics, Inc. (SYRE) on higher Unified Composite conviction (50.4/100 HOLD vs. 44.4/100 HOLD) after splitting the core matrix 2–3 (led by Options & Positioning), while SYRE wins 2–1 across the 6-pillar growth and valuation breakdown. SYRE trades at $99.60 (N/M Forward P/E, 0.0% operating margin) versus VTYX at $14.00 (N/M Forward P/E, 0.0% operating margin).
Growth vs. Quality Trade-Off: VTYX earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. SYRE 44.4/100 HOLD) and 2.07β · 2% Vol risk profile, whereas SYRE leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SYRE vs VTYX. Trailing 12-month operating profitability (SYRE 0.0% vs VTYX 0.0%) and valuation multiples (SYRE N/M vs VTYX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.0B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SYRE vs VTYX Key Questions & Quantitative Answers
As of Nov 16, 2026, Ventyx Biosciences, Inc. (VTYX) captures the overall head-to-head institutional edge over Spyre Therapeutics, Inc. (SYRE) on higher Unified Composite conviction (50.4/100 HOLD vs. 44.4/100 HOLD) after splitting the core matrix 2–3 (led by Options & Positioning), while SYRE wins 2–1 across the 6-pillar growth and valuation breakdown. SYRE trades at $99.60 (N/M Forward P/E, 0.0% operating margin) versus VTYX at $14.00 (N/M Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: VTYX earns the overall head-to-head edge with a stronger Unified Composite Score (50.4/100 HOLD vs. SYRE 44.4/100 HOLD) and 2.07β · 2% Vol risk profile, whereas SYRE leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
SYRE and VTYX split Growth & Scale metrics: SYRE posts +0.0% YoY revenue growth and -99.7% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VTYX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SYRE generates N/A in USD-normalized revenue versus N/A for VTYX. In operating R&D and SG&A reinvestment, SYRE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTYX.
SYRE and VTYX trade at balanced relative valuation multiples. SYRE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VTYX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SYRE (-35.0% ROE) versus VTYX (-45.4% ROE) capital efficiency.
In options market volatility and institutional positioning, SYRE carries 87.9% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.74β · 58% Vol realized risk). By comparison, VTYX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.07β · 2% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.